Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma, Malignant × Vorinostat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 27 Precursor Cell Lymphoblastic Leukemia-Lymphoma 24 Lymphoma 23 Multiple Myeloma 21 Lymphoma, Large B-Cell, Diffuse 20 Carcinoma, Non-Small-Cell Lung 20 Breast Neoplasms 20 Lymphoma, Non-Hodgkin 18 Lymphoma, Mantle-Cell 15 Lymphoma, Follicular 15 Hodgkin Disease 15 Lymphoma, T-Cell, Cutaneous 13 Leukemia, Lymphocytic, Chronic, B-Cell 12 Myelodysplastic Syndromes 11 Mycosis Fungoides 11 Lymphoma, B-Cell, Marginal Zone 11 Glioblastoma 11 Burkitt Lymphoma 11 Brain Neoplasms 11 Recurrence 10 Neuroblastoma 10 Leukemia 10 Sezary Syndrome 9 Congenital Abnormalities 9 Neoplasms 8 Lymphoma, Large-Cell, Anaplastic 8 Squamous Cell Carcinoma of Head and Neck 7 Prostatic Neoplasms 7 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7 Neoplasms, Plasma Cell 7

Interventions

Cisplatin 54 Pemetrexed 43 pembrolizumab 16 Nivolumab 14 Carboplatin 14 Gemcitabine 13 Cyclophosphamide 10 Radiotherapy 9 Drug Therapy 8 atezolizumab 7 Ipilimumab 7 durvalumab 6 Platinum 6 Doxorubicin 6 1,2-diaminocyclohexaneplatinum II citrate 6 tremelimumab 5 sodium thiosulfate 5 Vinorelbine 5 Radiotherapy, Intensity-Modulated 5 Chemotherapy, Adjuvant 5 Cerebral Decortication 5 sargramostim 4 defactinib 4 tumor necrosis factor-alpha, CNGRC fusion protein, human 3 Photochemotherapy 3 Neoadjuvant Therapy 3 Mitomycin 3 Interleukin-2 3 Dihematoporphyrin Ether 3 Decitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01353482 2012-03-22

MESO-02

University College, London

Phase 1/2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡